Revolution Medicines (RVMD) Non Operating Income (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Non Operating Income of -$8.6 million for Q1 2026, down 131.43% year-over-year from $27.3 million in Q1 2025, and down 163.14% quarter-over-quarter from -$3.3 million in Q4 2025.
Revolution Medicines (RVMD) Non Operating Income (2019 - 2026) Analysis & Trends
Revolution Medicines' Non Operating Income history runs 8 years deep, the most recent figure standing at -$8.6 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 131.43% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at $15.1 million (down 83.4% YoY), while the FY2025 annual figure was $51.1 million, down 42.41% from the prior year.
- Non Operating Income for Q1 2026 stood at -$8.6 million, down from -$3.3 million in the prior quarter.
- The five-year high for Non Operating Income was $27.3 million in Q1 2025, with the low at -$8.6 million in Q1 2026.
- The 5-year median for Non Operating Income is $10.5 million (2023), against an average of $11.0 million.
- The sharpest annual moves came in 2023 and 2026: Non Operating Income jumped 2237.42% in 2023, then sank 131.43% in 2026.
- Revolution Medicines' Non Operating Income stood at $5.1 million in 2022, then jumped by 270.08% to $18.8 million in 2023, then gained by 11.7% to $21.0 million in 2024, then sank by 115.56% to -$3.3 million in 2025, then slumped by 163.14% to -$8.6 million in 2026.
- Business Quant data shows RVMD's Non Operating Income at -$8.6 million in Q1 2026, -$3.3 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -139.24 Mn |
| Mar 31, 2026 | -8.59 Mn |
| Dec 31, 2025 | -3.27 Mn |
| Sep 30, 2025 | 10.06 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | 27.34 Mn |
| Dec 31, 2024 | 20.99 Mn |
| Sep 30, 2024 | 19.42 Mn |
| Jun 30, 2024 | 23.41 Mn |
| Mar 31, 2024 | 24.86 Mn |
| Dec 31, 2023 | 18.79 Mn |
| Sep 30, 2023 | 10.95 Mn |
| Jun 30, 2023 | 10.50 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 5.08 Mn |
| Sep 30, 2022 | 2.91 Mn |
| Jun 30, 2022 | 867,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 223,000.00 |